natera | Prospera™ Transplant assessment

As the experts in cell-free DNA (cfDNA) testing, we have refined our workflow based on our findings from two million cfDNA tests to now include **a proprietary technique to quantify absolute background cfDNA** in a streamlined manner.

This enhancement provides additional information to the physician when assessing rejection and may assist in identifying patients at-risk of a false negative interpretation.

Defining background cell-free DNA and its influence on your result

Background cell-free DNA originates from the transplant recipient and is naturally occurring in variable amounts within the plasma.



When the amount of background cfDNA is atypical, it impacts the percentage of dd-cfDNA and may compromise the depiction of risk for active rejection.

Factors that may influence background DNA may include:

- High body mass index (BMI)[1]
- Sepsis[2]
- Age[3]
- Surgery[4]
- Shipment and storage of sample[5]
- Chemotherapy[6]
- Normal variation[7]
- Myocardial infarction[8]
- Hemodialysis[9]
- Rejection

Providing greater precision for even more confidence in your Prospera result

Based on our leadership in cell-free DNA innovation, Natera has now introduced two novel techniques to provide greater precision.

1. Proprietary Library Preparation

Proprietary library preparation step that adjusts for background cfDNA introduced into the sample during transport

+

2. Quantifed Background CfDNA

Unique quantification method that can identify atypical background cfDNA that may influence the reported result for a particular patient



=

Potentially fewer false negative interpretations

What you can expect with your Prospera results

As part of your Prospera report, Natera will notify you when a patient has atypically high background (total) DNA, indicating a risk for a potential false negative interpretation.

Our clinical team is here to discuss these findings further and how to apply these personalized results into your care decisions for each patient.

Patients may be eligible to participate in an ongoing research protocol, the Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection **"SPARO,"** to improve the test performance and utility.

Clinical notification if sample has atypical background cell-free DNA



Patient Information

Patient Name:	Doe Jane
Date of Birth:	01/01/1980
Patient ID:	P99457
Medical Record #:	LP1234567
Transplant Date:	06/07/2018
Collection Kit #:	123456-2-N
Accessioning ID:	N/A
Case File ID:	101

Test information

Ordering Physician:	Dr. Matthew Smith, M.D. (G123456)
Clinic:	Natera, Inc.
Report Date:	10/07/2019
Transplanted Organ:	Kidney
Samples Collected:	08/04/2019
Samples Received:	08/04/2019

Prospera™
Transplant assessment

Prospera assesses transplanted kidney injury by reporting the percentage of **donor-derived cell-free DNA (dd-cfDNA)** in a recipient's blood.

CURRENT TEST RESULT

dd-cfDNA **0.59%**

REFERENCE RANGE
>/= 1%: Increased Risk for Active Rejection
< 1%: Decreased Risk for Active Rejection

Test Clinical Notes

Call us at 650.273.4468 to speak to our clinical team.

References

1. Vora NL, Johnson KL, Basu S, Catalano PM, Hauguel-De Mouzon S, Bianchi DW. A multifactorial relationship exists between total circulating cell-free DNA levels and maternal BMI. Prenat Diagn. 2012;32(9):912–914. doi:10.1002/pd.3919
2. Ahmed AI, Soliman RA, Samir S Cell Free DNA and Procalcitonin as Early Markers of Complications in ICU Patients with Multiple Trauma and Major Surgery. Clin Lab. 2016 Dec 1;62(12):2395-2404
3. Anker, P., Stroun, M., 2000. Circulating DNA in plasma or serum. Medicina (B Aires) 60, 99–702
4. Yu Qi,1 Tokujiro Uchida,1 Mamoru Yamamoto,1 Yudai Yamamoto,1 Koji Kido,1 Hiroyuki Ito,1 Nagara Ohno,2 Miho Asahara,2 Yoshitsugu Yamada,2 Osamu Yamaguchi,3 Chieko Mitaka,1 Makoto Tomita,4 and Koshi Makita Perioperative Elevation in Cell-Free DNA Levels in Patients Undergoing Cardiac Surgery: Possible Contribution of Neutrophil Extracellular Traps to Perioperative Renal Dysfunction. Anesthesiology Research and Practice Volume 2016, Article ID 2794364, 11 pages
5. Page, K., Guttery, D.S., Zahra, N., Primrose, L., Elshaw, S.R., Pringle, J.H., Blighe, K., Marchese, S.D., Hills, A., Woodley, L., Stebbing, J., Coombes, R.C., Shaw, J.A., 2013. Influence of plasma processing on recovery and analysis of circulating nucleic acids. PLoS One 8, e77963.
6. SWYSTUN, MUKHERJEE , LIAW. Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. Journal of Thrombosis and Haemostasis,9: 2313–2321
7. Stroun, M., Lyautey, J., Lederrey, C., Olson-Sand, A., Anker, P., 2001b. About the possible origin and mechanism of circulating DNA. apoptosis and active DNA release. Clin Chim Acta 313, 139–142.
8. Chang, Rhu-Hsin, Tsu-Lan et al. Elevated cell-free serum DNA detected in patients with myocardial infarction. Chimica Acta Volume 327, Issues 1–2, January 2003, Pages 95-101
9. Tovbin, Novack, Wiessman, Elkadir, Zlotnik, Douvdevani. Circulating cell-free DNA in hemodialysis patients predicts mortality Nephrology Dialysis Transplantation, Volume 27, Issue 10, October 2012, Pages 3929–3935

201 Industrial Road, Suite 410 | San Carlos, CA 94070 | www.natera.com | 1.650.249.9090 | Fax 1.650.730.2272

natera™
Conceive. Deliver. Thrive.